Last Price
3.16
Today's Change
-0.01 (0.31%)
Day's Change
3.08 - 3.21
Trading Volume
91,599
Market Cap
38 Million
Shares Outstanding
12 Million
Avg Volume
382,138
Avg Price (50 Days)
8.64
Avg Price (200 Days)
28.09
PE Ratio
-0.70
EPS
-4.50
Earnings Announcement
11-Mar-2025
Previous Close
3.16
Open
3.16
Day's Range
3.08 - 3.21
Year Range
2.9 - 53.79
Trading Volume
91,599
1 Day Change
-0.32%
5 Day Change
-3.66%
1 Month Change
-10.48%
3 Month Change
-93.34%
6 Month Change
-92.12%
Ytd Change
-8.41%
1 Year Change
-75.29%
3 Year Change
-95.71%
5 Year Change
-98.99%
10 Year Change
-99.06%
Max Change
-99.06%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.